Ss Innovations International, INC

SS Innovations International will showcase its SSi Mantra surgical robotic system at the 2026 Society of Robotic Surgery Annual Meeting, featuring a live kidney telesurgery and multiple breakout sessions.

SS Innovations International, Inc. announced the appointment of Sarah M. Romano as its new Chief Financial Officer, effective August 3, 2026, bringing extensive public company and capital markets experience.

SS Innovations International's subsidiary, SS International Centre for Robotics Surgery, has successfully graduated its inaugural class of 33 participants in a specialized cardiac robotic surgery training program.

SS Innovations International, Inc. has been recognized as the Outstanding Company at the 2026 Surgical Robotics Industry Awards for its advancements in robotic surgery.

SS Innovations International, Inc. has entered into an At-the-Market (ATM) Sales Agreement with Virtu Americas LLC to offer up to $50 million of its common stock.

SS Innovations International, Inc. (SSII) released its June 2026 Company Presentation, highlighting advancements in its SSi Mantra surgical robotic system, global expansion plans, and strong sales growth.

SS Innovations International, Inc. reported a significant increase in revenue for the first quarter of 2026, driven by strong system and instrument sales, while also addressing ongoing operational and financial considerations.

SS Innovations International, Inc. reports significant revenue growth and a reduced net loss for the first nine months of 2025, driven by increased surgical robotic system sales, despite ongoing operational losses and internal control weaknesses.

SS Innovations International, Inc. reported significant revenue growth and reduced net losses for Q2 and H1 2025, but faces substantial doubt about its ability to continue as a going concern.

SS Innovations International saw revenue climb and net losses shrink in the first quarter of 2025, driven by increased system and instrument sales.

SS Innovations International restated its Q3 2024 financials due to material errors and weaknesses in internal controls, leading to a re-evaluation of financial reporting effectiveness.

SS Innovations International amended its Q2 2024 report to restate financial statements due to material errors and ineffective internal controls, following a change in auditors.

SS Innovations International, Inc. filed an amendment to its 2025 annual report to include a new executive compensation clawback policy and updated certifications.

SS Innovations International's 2024 10-K filing reveals a significant revenue increase driven by surgical robotic system sales, but also highlights substantial doubt about the company's ability to continue as a going concern due to recurring losses and dependence on external funding.

SS Innovations International filed an amendment to its annual report to correct a typographical error and restate prior financials due to errors in merger accounting, functional classifications, revenue recognition, and lease accounting.

SS Innovations International has restated its financial statements for 2022 and 2023 due to material accounting errors and a change in auditors, revealing ineffective internal controls.

SS Innovations International reports a significant increase in revenue for 2023, driven by sales of its SSi Mantra surgical robotic system, while also highlighting ongoing efforts in research and development and regulatory approvals.

CEO of Asia Pacific, Vishwajyoti Pascual Srivastava, acquired 1,000,000 shares of SS Innovations International, Inc. via a gift.

Chairman and CEO Sudhir Srivastava reported a gift transfer of 1,000,000 shares of SS Innovations International, Inc. common stock.

COO Barry F. Cohen reported a gift of 25,000 shares of SS Innovations International, Inc. common stock.

Chairman and CEO Sudhir Srivastava reported the transfer of 21,506 shares of SS Innovations International, Inc. common stock as part of a settlement agreement.

Chairman and CEO Sudhir Srivastava reported a gift of 10,000 shares of SS Innovations International, Inc. common stock.

Barry F. Cohen, Director and COO - Americas of SS Innovations International, Inc. (SSII), reported a transaction involving the disposal of 19,000 common shares to satisfy a personal promissory note.

SS Innovations International, Inc. filed an S-1 registration statement for a $50 million common stock offering, highlighting significant revenue and installation growth for its SSi Mantra surgical robotic system, despite ongoing net losses and a 'going concern' warning.

SS Innovations International, a surgical robotics company, is seeking to raise capital through an IPO to expand its manufacturing capacity, conduct clinical trials, and establish marketing offices.

Frederic H. Moll has filed an amended Schedule 13G, revealing a beneficial ownership of 11.26% in SS Innovations International, Inc. as of March 31, 2025.

Dr. Sudhir Srivastava and affiliated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 60.60% of SS Innovations International, Inc.'s common stock as of March 31, 2025.

Barry F. Cohen has reported a 5.4% beneficial ownership stake in SS Innovations International, Inc., comprising 9,177,717 shares of common stock as of December 31, 2024.

Dr. Sudhir Srivastava and affiliated entities have filed an amended Schedule 13G, revealing a significant beneficial ownership stake of 63.1% in SS Innovations International, Inc.'s common stock as of December 31, 2024.

Frederic H. Moll has filed an amended Schedule 13G, reporting a beneficial ownership of 10.6% in SS Innovations International, Inc. as of December 31, 2024.

An amended Schedule 13G filing reveals that Ranjan R. Pai and Manipal Global Health Services collectively hold an 8.7% beneficial ownership stake in SS Innovations International, Inc. as of December 31, 2024.